Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29152812 | 0.79 | ALOX15 (0.49) | ALDH1A1MAPTALOX15LMNAHPGD | |
| SCHEMBL4264795 | 0.77 | NAPRT (0.54) | ALDH1A1MAPTALOX15LMNAHPGD | |
| SCHEMBL523863 | 0.73 | MAPT (0.49) | ALDH1A1MAPTALOX15LMNAHPGD | |
| SCHEMBL9148337 | 0.73 | LMNA (0.85) | ALDH1A1MAPTALOX15LMNAHPGD | |
| SCHEMBL1424601 | 0.73 | ALOX15 (0.66) | ALDH1A1MAPTALOX15LMNAHPGD | |
| SCHEMBL4419093 | 0.73 | MAPT (0.53) | ALDH1A1MAPTLMNAHSD17B10KMT2A | |
| SCHEMBL31061107 | 0.73 | MAPT (0.53) | ALDH1A1MAPTLMNAHSD17B10KMT2A | |
| SCHEMBL27774649 | 0.72 | IDO1 (0.56) | ALDH1A1MAPTALOX15LMNAHPGD | |
| SCHEMBL182010 | 0.72 | CES2 (0.71) | ALDH1A1ALOX15LMNAHPGDHSD17B10 | |
| SCHEMBL4422728 | 0.71 | ALDH1A1 (0.51) | ALDH1A1MAPTLMNAHSD17B10HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1689394-A4 | AMINO SUBSTITUTED PYRIDINYL METHANONE COMPOUNDS USEFUL IN TREATING KINASE DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-03 | — | — | EP | disclosed |
| US-7109220-B2 | Amino substituted pyridinyl methanone compounds useful in treating kinase disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-09-19 | — | — | US | disclosed |
| EP-1689394-A1 | AMINO SUBSTITUTED PYRIDINYL METHANONE COMPOUNDS USEFUL IN TREATING KINASE DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-16 | — | — | EP | disclosed |
| US-20050124610-A1 | Amino substituted pyridinyl methanone compounds useful in treating kinase disorders | JANSSEN PHARMACEUTICA N. V. (BE) | 2005-06-09 | — | — | US | disclosed |
| WO-2005051387-A1 | AMINO SUBSTITUTED PYRIDINYL METHANONE COMPOUNDS USEFUL IN TREATING KINASE DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124610-A1 | Amino substituted pyridinyl methanone compounds useful in treating kinase disorders | CDK6, CDK1, CDK3 | ALDH1A1 2979/4885MAPT 2602/4885ALOX15 2735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.